IYH iShares U.S. Healthcare ETF

iShares U.S. Healthcare ETF (IYH) currently reports 100 stock positions (subject to change), placing it in the balanced in breadth range by holdings breadth. The top line-up is LLY (14.74%), JNJ (9.79%), ABBV (7.53%), with LLY as the largest single weight at 14.74%. Together, the top three holdings account for 32.06%, which creates a leadership-driven return profile where the top names carry disproportionate influence over fund outcomes. In aggregate, the construction reflects a balance between directional conviction and the diversification benefits that come from a broader holding set.

On the question of capital productivity, ROIC is 21.19%, WACC is 6.80%, and the economic spread is 14.39%. On balance, the economic spread is positive and meaningful, suggesting the underlying holdings are building rather than eroding intrinsic value. Supporting metrics show ROE at 30.52% and ROA at 8.90%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a portfolio with credible compounding capacity if current operating execution persists.

Assessed on a multiple basis, trailing P/E of 30.89, forward P/E of 18.86, PEG of 2.65. The difference between trailing and forward multiples is significant, suggesting investors are paying today for earnings that have not yet been fully delivered. At this PEG level, the valuation case rests more on quality, scarcity, or market leadership than on earnings growth alone. The portfolio carries an aggregate current ratio of 1.80, consistent with adequate near-term liquidity management. Overall, the valuation setup reads as a balance between expected growth and execution risk, with liquidity acting as an important stabilizer if macro conditions become less favorable.

The margin stack reads as follows: gross margin sits at 61.47%, operating margin at -27.77%, and free cash flow margin at 21.09%. Gross margins at this level typically indicate businesses with structural pricing advantages and low direct cost sensitivity. Operating margins this compressed indicate businesses where the path to earnings remains dependent on future scale. FCF margins are constructive here, reflecting holdings that generate cash reliably after reinvestment requirements. The margin profile is a mixed read — some holdings are clearly well-run, but the aggregate numbers point to a basket that is not uniformly high-quality.

Where growth and expectations intersect, the estimated 12-month price change of 11.70%, where analyst assumptions support a moderate upside case if execution remains steady, while TTM revenue growth of 16.92% suggesting the portfolio's holdings are growing revenues at a measured, sustainable pace. The projected 12-month EPS growth rate of 63.8% is a standout component of the forward case — meaningful earnings expansion at this scale typically warrants attention from growth-oriented investors. Both signals are useful lenses, but they tend to diverge most sharply near inflection points in both business fundamentals and market sentiment. The durability of both the operating trend and analyst optimism will determine whether the current setup translates into measurable near-term returns. The estimated 12-month price change is a weighted composite of analyst price target estimates adjusted by each holding's ETF weight, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The overall evidence base is constructive, with more signals pointing up than down and no obvious structural impairment to the forward case.

These findings are based solely on the metrics presented and do not constitute an investment recommendation. Always perform your own due diligence before committing capital.